City of Hope Comprehensive Cancer Center

Beckman Research Institute

Duarte, CA

Accepting patients

Orca-T

A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Learn more
  • Allogeneic Stem Cell Transplant
  • T Cell (Allogeneic)
  • Phase 3
  • Has results

Accepting patients

Mismatched Related vs. Matched Unrelated Donor

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

Total Marrow and Lymphoid Irradiation

Phase II Study of Evaluating the Efficacy of Total Marrow and Lymphoid Irradiation (TMLI) as the Conditioning Regimen for HLA-Haploidentical Hematopoietic Cell Transplantation in Patients With Myelodysplasia or Acute Leukemia
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

BTX-A51

A First-In-Human, Open-Label, Escalating Multiple-Dose Study to Evaluate the Safety, Toxicity, and Pharmacokinetics of BTX-A51 Capsules in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Learn more
  • Cyclin-Dependent Kinase Inhibitor
  • Kinase Inhibitor
  • Phase 1
  • Has results

Accepting patients

TWT-202

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML
Learn more
  • Hypomethylating Agents (HMA)
  • PLK4 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

JSP191 Conditioning Regimen

A Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation & Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 1
  • Has results

Accepting patients

BGB-11417

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

CG-806

A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Learn more
  • BTK Inhibitor
  • Phase 1

Accepting patients

A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Learn more
  • Cyclin-Dependent Kinase Inhibitor
  • Phase 1/2

Accepting patients

Basiliximab

Phase I Study of Escalating Doses of 90Y-DOTA-Anti-CD25 Monoclonal Antibody Added to the Conditioning Regimen of Fludarabine, Melphalan, and Organ Sparing Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Learn more
  • Chemotherapy
  • Monoclonal Antibody
  • CD25
  • Radiation
  • Phase 1
4 trials are hidden based on your filters. Show All